Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cobamamide, also known as coenzyme B12 or dibencozide, is a small molecule and the active coenzyme form of vitamin B12. Developed and manufactured by Guilin Hwasun as an oral capsule, it is used primarily for its metabolic and neuroprotective properties. Unlike cyanocobalamin, cobamamide does not require hepatic conversion to become biologically active. It serves as an essential cofactor for enzymes such as methylmalonyl-CoA mutase, which is critical for the metabolism of amino acids and fatty acids, and the synthesis of hemoglobin. It is clinically indicated for the treatment of megaloblastic anemia, peripheral neuropathies, and various metabolic disorders associated with vitamin B12 deficiency.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cobamamide.